Skip to main content
KBS_Icon_questionmark link-ico

Biography

Huajie Jin (Lily) joined King’s College London (KCL) in 2013 as a senior health economist. Her research focuses on economic modelling and trial-based economic evaluation for mental health disorders and cancer.

Lily gained a BSc in Medicine in the People’s Republic of China in 2008 and completed her MSc in International Health Policy (health Economics stream) at the London School of Economics and Political Science in 2009. Following the completion of her MSc, she worked on the NICE (National Institute for Health and Care Excellence) clinical guidelines for three years: first year as a systematic reviewer, second and third year as a health economist. Since Lily joined KCL in 2013 as a senior health economist, she has been working on a part-time PhD, which aims to build an individual patient level whole disease model (WDM) covering the entire care pathway for schizophrenia service in the UK. This WDM can be used to compare the cost-effectiveness of all key interventions for schizophrenia patients, including CBT, family intervention, antipsychotics, and crisis resolution and home treatment team. Lily submitted her PhD thesis in July 2019 and is expected to have her viva in Sep 2019.

Lily is currently working on the following projects:

  • NICE Medtech innovation briefings (MIB). Lily’s role is to provide economic evidence of new medical devices that are under consideration of the NHS and social care commissioners and staff.
  • PROSPECTS: A 7-year multi-centre clinical trial which aims to compare the cost-effectiveness of breast cancer screening using DBT + 2DDM or S2D with screening using 2DDM. This study aims to recruit 100,000 women aged 50-70 years who are attending for routine screening. Lily will compare the cost-effectiveness of different screening methods by analysing the Hospital Episode Statistics (HES) database and building a discrete-event simulation (DES) model.
  • STRATA: A 5-million multi-centre clinical trial which aims to develop a precision medical algorithm for people with schizophrenia. Lily has built three Markov models to evaluate the cost-effectiveness of the proposed precision medical algorithm.
  • SABR: Lily built three Markov models to evaluate the cost-effectiveness of Stereotactic ablative radiotherapy (SABR) for three patient groups: patients with oligometastatic disease; a small hepatocellular carcinoma (HCC) with Child-Pugh class A liver function; and re-occurrence of malignancy in the spine or pelvic region.
  • LQD Study: A one-year clinical trial which aims to assess which add-on therapies are more likely to improve depression symptoms for people with treatment resistant depression: lithium or quetiapine. Lily will conduct a trial-based economic analysis to assess the cost-effectiveness of both therapies.

Research Interests

  • Economic modelling
  • Whole disease model
  • Discrete event simulation
  • Markov model
  • Trial-based economic evaluation
  • Mental health disorders
  • Schizophrenia
  • Cancer

Expertise and Public Engagement 

  • 2013 to 2019: Peer view papers for the following journals: The Lancet Public Health, PharmacoEconomics, Clinical Journal of Psychiatry, European Psychiatry, International Journal of Molecular Sciences and Psychological Medicine.
  • Nov 2019: Oral presentation of the findings of the schizophrenia whole disease model at the London Health Economics Group (LHEG) meeting, City Health Economics Centre, City, University of London, London, UK.
  • Sep 2019: Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics Research Centre (HERC) Seminar Series, University of Oxford, UK.
  • July 2019: Oral presentation of the findings of the schizophrenia whole disease model at the HESG conference, Norwich.
  • June 2019: Oral presentation of the findings of the schizophrenia whole disease model at the 13th ENMESH conference, Portugal.
  • March 2019: Oral presentation of the findings of the schizophrenia whole disease model at the Fourteenth Workshop on Costs and Assessment in Psychiatry, Venice.
  • November 2016: Writing comment for Schizophrenia research forum: ‘The Societal Cost of Schizophrenia: New Evidence From the US’.
  • Dec 2015: Oral presentation of the findings from the LEGS study at the PKU China Centre for Health Economic Research Seminar, Beijing, P.R. China.
  • Feb 2012: Oral presentation of the development of NICE clinical guidelines at the PKU China Centre for Health Economic Research seminar, Beijing, P.R. China.